MREO

Price Chart

Key Financial Metrics

Key Facts

• Mereo entered an option and license agreement with Sentynl Therapeutics for U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
• Mereo receives a non-refundable option fee (amount undisclosed) and, on option exercise, is eligible for $40 million in upfront and R&D payments.
• Mereo is eligible for up to $435 million in regulatory and commercial milestone payments plus double-digit tiered royalties on U.S. net sales.
• Mereo retains rest-of-world commercial rights and will lead the global Phase 3 study and regulatory interactions.
• The Phase 3 study for alvelestat could be initiated in early 2027.
• Alvelestat has Orphan Drug Designation from the European Commission and FDA, and Fast Track designation from the FDA.
• Mereo's market cap is approximately $42M, making the potential deal value (up to $475M in upfront + milestones) highly significant relative to current valuation.

Financial Impact

Up to $40M in upfront and R&D payments on option exercise, plus up to $435M in milestones and double-digit tiered royalties. Non-refundable option fee amount not disclosed.

Risk Factors

• Option may not be exercised by Sentynl, leaving Mereo to fund Phase 3 alone.
• Phase 3 clinical trial risk — positive Phase 2 data does not guarantee Phase 3 success.
• Regulatory risk: FDA/EMA approval not guaranteed despite Orphan and Fast Track designations.
• Commercial risk: alvelestat would be first oral treatment for AATD-LD but faces entrenched augmentation therapy standard of care.
• Mereo's $42M market cap implies limited financial flexibility if the option is not exercised or if additional capital is needed.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

US Market Status